What recent returns say about HealthEquity
HealthEquity (HQY) has drawn attention after a recent move in its share price, with the stock showing a 1.5% gain over the past day and a 2.6% rise over the past week.
Over the past month the stock return sits around 5.9%, while the past 3 months show a 7.0% decline, giving investors a mixed short term picture to weigh against longer term performance.
See our latest analysis for HealthEquity.
At a share price of $84.67, HealthEquity’s recent 30 day share price return of 5.9% contrasts with a 90 day share price return of negative 7.0%. The 1 year total shareholder return of 7.5% and 3 year total shareholder return of 48.6% point to stronger momentum over longer periods.
If you are weighing HealthEquity’s recent moves against similar ideas in the sector, it can help to see what else is setting the pace in 36 healthcare AI stocks
HealthEquity’s shares now sit around $84.67, with recent returns, solid 1 year and 3 year gains, and an implied discount to some valuation estimates all pulling in different directions. Is this a genuine opening, or is future growth already priced in?
Most Popular Narrative: 24.1% Undervalued
At $84.67, the most followed narrative on HealthEquity points to a fair value of about $111.63, implying meaningful upside if its assumptions play out.
The recent regulatory expansion, allowing direct primary care, pre-deductible telehealth, and millions of new ACA bronze/catastrophic plan members to qualify for HSAs, creates the largest addressable market increase in two decades, poised to accelerate new account openings and AUM growth, meaningfully boosting future revenue.
Want to see what is baked into that view? The narrative leans on steady revenue gains, rising margins, and a future earnings multiple that has to stay elevated. The full story is in how those ingredients are combined and discounted.
Result: Fair Value of $111.63 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on a healthy labor market and supportive interest rates, since slower hiring or lower custodial yields could quickly challenge those upbeat assumptions.
Find out about the key risks to this HealthEquity narrative.
Another way to look at HealthEquity’s valuation
The first narrative leans heavily on future earnings and fair value estimates, but the current P/E of 33.2x tells a different story. That is higher than the US Healthcare industry at 22x, the peer average at 16.8x, and even the fair ratio of 25.7x. This suggests there may be less room for error if expectations slip.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals on price and valuation so far, it makes sense to pressure test the numbers yourself and not just rely on headlines. To see which potential upsides are getting investors excited and to judge whether they still look attractive for you, take a closer look at the 4 key rewards
Looking for more investment ideas?
If HealthEquity has caught your eye, do not stop there. Broaden your opportunity set with other focused stock ideas that could better match your goals.
- Spot potential bargains early by checking companies highlighted in the 59 high quality undervalued stocks.
- Prioritise resilience by scanning the 68 resilient stocks with low risk scores for businesses with steadier risk profiles.
- Hunt for future standouts before the crowd notices through the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com